031

INTEGRATIVE ANALYSIS REVEALS A MOLECULAR STRATIFICATION OF SYSTEMIC AUTOIMMUNE DISEASES

¹Guillermo Barturen, ²Sepideh Babaei, ³Francesc Català-Moll, ¹Manuel Martínez-Bueno, ²Zuzanna Makowska, ⁴Jordi Martorell-Marugán, ⁴Pedro Carmona-Sáez, ¹Daniel Toro-Domínguez, ¹Elena Camero-Montoro, ⁵Martin Kerick, ⁵Marialbert Acosta-Herrera, ⁶Lucas Le Lann, ⁶Christophe Jamin, ³Javier Rodríguez-Ubreva, ³Antonio García-Gómez, ²Jorge Kageyama, ²Anne Buttgerit, ²Sikander Hayat, ²Joerg Mueller, ²Ralf Lesche, ⁷Maria Hernandez-Fuentes, ⁷Maria Juarez, ⁷Tania Rowley, ⁷Ian White, ¹Concepción Marañón, ¹Tania Gomes Anjos, ¹Nieves Varela, ⁸Rocío Aguilar-Quesada, ⁸Francisco Javier Garrancho, ⁸Antonio López-Berrio, ⁸Manuel Rodríguez Maresca, ⁸Héctor Navarro-Linares, ⁹Isabel Almeida, ¹⁰Nancy Azevedo, ⁹Mariana Brandão, ⁹Ana Campar, ⁹Raquel Faria, ⁹Fátima Farinha, ⁹António Marinho, ¹⁰Esmeralda Neves, ⁹Ana Tavares, ⁹Carlos Vasconcelos, ¹¹Elena Trombetta, ¹²Gaia Montanelli, ¹²Barbara Vigone, ³Damiana Alvarez-Errio, ³Tianlu Li, ¹³Ricardo Blanco Alonso, ¹³Alfonso Corrales Martínez, ¹³Fernanda Genre, ¹³Raquel López Mejías, ¹³Miguel A Gonzalez-Gay, ¹³Sara Remuzgo, ¹³Begoña Ubilla García, ¹⁴Ricard Cervera, ¹⁴Gerard Espinosa, ¹⁴Ignasi Rodríguez-Pintó, ¹⁵Ellen De Langhe, ¹⁵Jonathan Cremer, ¹⁵Rik Lories, ¹⁶Doreen Belz, ¹⁶Nicolas Hunzelmann, ¹⁷Niklas Baerlecken, ¹⁷Katja Kniesch, ¹⁷Torsten Witte, ¹⁸Michaela Lehner, ¹⁸Georg Stummvoll, ¹⁸Michael Zauner, ¹⁹Maria Angeles Aguirre-Zamorano, ¹⁹Nuria Barbarroja, ¹⁹Maria Carmen Castro-Villegas, ¹⁹Eduardo Collantes-Estevez, ²⁰Enrique de Ramon, ²⁰Isabel Diaz Quintero, ¹⁹Alejandro Escudero-Contreras, ²¹Maria Concepción Fernández Roldán, ¹⁹Yolanda Jiménez Gómez, ²²Inmaculada Jiménez Moleón, ¹⁹Rosario Lopez-Pedraza, ¹⁹Rafaela Ortega-Castro, ²¹Norberto Ortego, ²²Enrique Raya, ²³Carolina Artusi, ²³Maria Gerosa, ²³Pier Luigi Meroni, ²³Tommaso Schioppa, ²⁴Aurélien De Groof, ²⁴Julie Ducreux, ²⁴Bernard Lauwerys, ²⁴Anne-Lise Maudoux, ⁶Divi Cornec, ⁶Valérie Devauchelle-Pensec, ⁶Sandrine Jousse-Joulin, ²⁵Pierre-Emmanuel Jouve, ⁶Bénédicte Rouvière, ⁶Alain Sarau, ⁶Quentin Simon, ²⁶Montserrat Alvarez, ²⁶Carlo Chizzolini, ²⁶Aleksandra Dufour, ²⁶Donatienne Wynar, ²⁷Attila Balog, ²⁷Márta Bocskai, ²⁷Magdolna Deák, ²⁷Sonja Dulic, ²⁷Gabriella Kádár, ²⁷László Kovács, ²⁸Qingyu Cheng, ²⁸Velia Gerl, ²⁸Falk Hiepe, ²⁸Laleh Khodadadi, ²⁸Silvia Thiel, ²⁹Emanuele de Rinaldis, ³⁰Sambasiva Rao, ³¹Robert J Benschop, ³¹Chris Chamberlain, ³¹Ernst R Dow, ³¹Yiannis Ioannou, ³²Laurence Laigle, ⁷Jacqueline Marovac, ³³Jerome Wojcik, ⁶Yves Renaudineau, ^{23,34}Maria Orietta Borghi, ³⁵Johan Frostegård, ³⁵Javier Martín, ¹²Lorenzo Beretta, ³Esteban Ballestar, ²Fiona McDonald, ⁶Jacques-Olivier Pers, ^{1,3}Marta E Alarcón-Riquelme. ¹Dept. of Medical Genomics, Center for Genomics and Oncological Research (GENYO), Granada, Spain; ²Pharmaceuticals Division, Bayer Pharma Aktiengesellschaft, Berlin, Germany; ³Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona; ⁴Dept. of Bioinformatics, Center for Genomics and Oncological Research (GENYO), Granada; ⁵Institute of Parasitology and Biomedicine López Neyra, Spanish National Research Council, Granada, Spain; ⁶Université de Brest, INSERM, Labex IGO, CHU de Brest, Brest, France; ⁷UCB Pharma, Slough, UK; ⁸Andalusian Public Health System Biobank, Granada, Spain; ⁹Unidade de Imunologia Clínica, Centro Hospitalar do Porto; ¹⁰Serviço de Imunologia EX-CICAP, Centro Hospitalar e Universitário do Porto, Porto, Portugal; ¹¹Laboratorio di Analisi Chimico Cliniche e Microbiologia – Servizio di Citofluorimetria, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy; ¹²Scleroderma Unit, Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy; ¹³Servicio Cántabro de Salud, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander; ¹⁴Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain; ¹⁵Skeletal Biology and Engineering Research Center, KU Leuven and Division of Rheumatology, UZ Leuven, Leuven, Belgium; ¹⁶Klinikum der Universität zu Köln, Cologne; ¹⁷Klinik für Immunologie und Rheumatologie, Medical University Hannover, Hannover, Germany; ¹⁸Medical University Vienna, Vienna, Austria; ¹⁹Rheumatology Service, Reina Sofia Hospital, Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC), University of Cordoba, Cordoba; ²⁰Servicio Andaluz de Salud, Hospital Regional Universitario de Málaga; ²¹Servicio Andaluz de Salud, Complejo Hospitalario Universitario de Granada (Hospital Universitario San Cecilio); ²²Servicio Andaluz de Salud, Complejo Hospitalario Universitario de Granada (Hospital Virgen de las Nieves), Granada, Spain; ²³Università degli studi di Milano, Milan; ²⁴Pôle de Pathologies Rhumatismales Inflammatoires et Systémiques, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium; ²⁵AltraBio SAS, Lyon, France; ²⁶Immunology and Allergy, University Hospital and School of Medicine, Geneva, Switzerland; ²⁷University of Szeged, Szeged, Hungary; ²⁸Dept. of Rheumatology and Clinical Immunology, Charité University Hospital, Berlin, Germany; ²⁹Precision Immunology Cluster, Sanofi, Cambridge; ³⁰Sanofi Genzyme, Framingham; ³¹Eli Lilly and Company, Indianapolis, USA; ³²Institut de Recherches Internationales Servier, Suresnes, France; ³³QuartzBio, SA, Geneva, Switzerland; ³⁴Istituto Auxologico Italiano, Milan, Italy;

³⁵Unit for Chronic Inflammatory Diseases, Institute for Environmental Medicine, Karolinska Institutet, Stockholm, Sweden

10.1136/lupus-2020-eurolupus.42

Background Clinical heterogeneity, a hallmark of systemic autoimmune diseases (SADs) impedes early diagnosis and effective treatment, issues that may be addressed if patients could be grouped into a molecular defined stratification.

Methods With the aim of reclassifying SADs independently of the clinical diagnoses, unsupervised clustering of integrated whole blood transcriptome and methylome cross-sectional data of 918 patients with 7 SADs and 263 healthy controls was undertaken. An inception cohort prospectively followed for 6 and 14 months was studied to validate the results in early cases and analyze if cluster assignment was modified with time.

Results

Four clusters were identified Three aberrant clusters were 'acute phase inflammatory', 'T cell immunity', and 'interferon', each including all diagnoses, were defined by genetic, clinical, serological and cellular features. A fourth cluster showed no specific molecular pattern, to which 74% of healthy controls clustered with patients. The inception cohort showed that most patients were either assigned always to the same cluster or moved from the healthy-like cluster to a single aberrant cluster resembling the relapsing-remitting dynamic of these diseases, showing that single aberrant molecular signatures characterize each individual patient.

Conclusions Patients with SADs share molecular signatures and can be therefore stratified into three disease clusters differentiating each patient into a specific molecular disease pathway. Such assignment is stable with time. These results have important implications for understanding disease progression and therapy design marking a paradigm shift in our view of SADs.

Acknowledgment This work has been supported through a grant from the Innovative Medicines Initiative Joint Undertaking No. 115565 and in-kind and in-cash contributions from the EFPIA partners. G.B. is supported by the Instituto de Salud Carlos III (ISCIII, Spanish Health Ministry), through the Sara Borrell subprogram (CD18/00153). The authors would like to particularly express their gratitude to the patients, nurses and many others who helped directly or indirectly in the consecution of this study.

032

SKIN PROTEOME INVESTIGATION IN CUTANEOUS LUPUS ERYTHEMATOSUS (CLE) REVEALS NOVEL UNIQUE DISEASE PATHWAYS

¹Timothy B Niewold, ²Alexander Meves, ²Julia Lehman, ³Karin Popovic-Silwerfeldt, ⁴Aleksandra Antovic, ⁵Jessica M Dorschner, ⁶Cristine M Charlesworth, ⁴Ingrid Lundberg, ⁴Marie Wahren-Herlenius, ⁴Elisabet Svenungsson, ⁴V Oke. ¹Colton Center for Autoimmunity, New York University, New York; ²Dept. of Dermatology, Mayo Clinic, Rochester, USA; ³Dermatology Clinic, Danderyds Hospital, Danderyds, Sweden; ⁴Rheumatology Unit, Dept. of Medicine, Karolinska Institutet, Stockholm, Sweden; ⁵Proteomics Core, Mayo Clinic, Rochester, USA; ⁶Division of Rheumatology and Dept. of Immunology, Mayo Clinic, Rochester, USA

10.1136/lupus-2020-eurolupus.43

Background Cutaneous Lupus Erythematosus (CLE) is an autoimmune disease. It can be limited to the skin or be one of